Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C19 or CYP3A5 Genotyping Does Not Predict Clinical Response to Clopidogrel.

Journal of clinical pharmacology - 1 Oct 2018

Rodríguez-González Fayna, Martínez-Quintana Efren, Saavedra Pedro, Medina-Gil José M, Riaño Marta, Garay-Sánchez Paloma, Tugores Antonio

Abstract excerpt

Along with aspirin, clopidogrel has been a widely used antiplatelet therapeutic regimen. Although generally well tolerated, its efficacy varies among individuals, with the main hypothesis that its bioavailability relies on its bioconversion to the active compound, which, in turn, depends on the genetic background and/or interactions with other drugs. To determine which factors influenced response in our patients,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Coronary Syndrome
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clopidogrel

Share to Cohort Studies

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP3A

Share to Genotype

Share to Platelet Aggregation Inhibitors

Source

Identifiers

PMID: 29723426
DOI: 10.1002/jcph.1144

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C19 or CYP3A5 Genotyping Does Not Predict Clinical Response to Clopidogrel.PMID 29723426Read ↗

Genetic determinants of response to clopidogrel and cardiovascular events.Semantic proximity Read ↗

Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.Semantic proximity Read ↗

Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.Semantic proximity Read ↗

Clopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery DiseaseSemantic proximity Read ↗

The ABCD-GENE score influences vascular event rates in both users of clopidogrel and aspirin, as well as non-users of either drug in a population-based cohort studySemantic proximity Read ↗

Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use.Semantic proximity Read ↗

CYP2C19 Pharmacogenetics and Clopidogrel Prescription in a University Hospital: A Descriptive Study in a Clinical Data WarehouseSemantic proximity Read ↗

Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke.Semantic proximity Read ↗

Genotyping of six clopidogrel-metabolizing enzyme polymorphisms has a minor role in the assessment of platelet reactivity in patients with acute coronary syndrome.Semantic proximity Read ↗

Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.Semantic proximity Read ↗

Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.Semantic proximity Read ↗

Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.